BioCentury
ARTICLE | Company News

Padlock secures GSK assets

May 29, 2015 2:41 AM UTC

Padlock Therapeutics Inc. (Cambridge, Mass.) licensed an asset package from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) related to peptidyl arginine deiminases (PADs). The assets include IP, undisclosed compounds, data sets and assays. Padlock CEO Michael Gilman declined to disclose specific financial details, but said GSK received a "meaningful amount" of equity; GSK's Rab Prinjha will join Padlock's board as an observer.

Padlock is developing a pipeline of PAD inhibitors to treat autoimmune disorders. PADs convert the amino acid arginine to citrulline and generate autoantigens that play a role in autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and multiple sclerosis (MS) (see BioCentury, Jan. 19). ...